As of 2025-03-21, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -6.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 2,205.98 mil USD. RXRX's TTM EBITDA according to its financial statements is -365.32 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 12.1x | 10.0x |
| Forward P/E multiples | 10.7x - 21.7x | 16.2x |
| Fair Price | (8.73) - (10.00) | (10.91) |
| Upside | -234.7% - -254.4% | -268.4% |
| Date | EV/EBITDA |
| 2025-03-21 | -5.99 |
| 2025-03-20 | -6.04 |
| 2025-03-19 | -6.15 |
| 2025-03-18 | -5.94 |
| 2025-03-17 | -6.43 |
| 2025-03-14 | -5.90 |
| 2025-03-13 | -5.44 |
| 2025-03-12 | -5.70 |
| 2025-03-11 | -5.58 |
| 2025-03-10 | -5.65 |
| 2025-03-07 | -6.16 |
| 2025-03-06 | -5.77 |
| 2025-03-05 | -6.15 |
| 2025-03-04 | -6.03 |
| 2025-03-03 | -6.16 |
| 2025-02-28 | -7.17 |
| 2025-02-27 | -7.35 |
| 2025-02-26 | -8.09 |
| 2025-02-25 | -7.87 |
| 2025-02-24 | -8.81 |
| 2025-02-21 | -9.12 |
| 2025-02-20 | -10.30 |
| 2025-02-19 | -10.87 |
| 2025-02-18 | -10.62 |
| 2025-02-14 | -10.49 |
| 2025-02-13 | -8.26 |
| 2025-02-12 | -8.09 |
| 2025-02-11 | -7.34 |
| 2025-02-10 | -7.33 |
| 2025-02-07 | -7.15 |
| 2025-02-06 | -6.87 |
| 2025-02-05 | -7.62 |
| 2025-02-04 | -7.28 |
| 2025-02-03 | -6.89 |
| 2025-01-31 | -6.87 |
| 2025-01-30 | -7.37 |
| 2025-01-29 | -6.79 |
| 2025-01-28 | -7.08 |
| 2025-01-27 | -6.64 |
| 2025-01-24 | -6.97 |
| 2025-01-23 | -7.19 |
| 2025-01-22 | -7.15 |
| 2025-01-21 | -6.48 |
| 2025-01-17 | -6.09 |
| 2025-01-16 | -5.95 |
| 2025-01-15 | -5.97 |
| 2025-01-14 | -5.86 |
| 2025-01-13 | -6.32 |
| 2025-01-10 | -6.48 |
| 2025-01-08 | -6.90 |